Candela Corporation (Candela), a US-based manufacturer, and distributer of clinical solutions, has reported revenues of $116.6 million for fiscal 2009, compared with the revenue of $146.6 million in the previous year-end. It has also reported a net loss of $22.3 million, or $0.98 loss per diluted share, for fiscal 2009, compared with the net loss of $9.1 million, or $0.40 loss per diluted share, in the previous year-end.
The revenues for the quarter ended June 27, 2009 were $31.4 million. Income from continuing operations, including non-cash expenses of $1.5 million, was $380,000 or $0.02 per share on a fully-diluted basis. Income from discontinued operations, net of income taxes, was $6,758,000 or $0.29 per share on a fully-diluted basis. Net income for the quarter was $7,138,000 or $0.31 per share on a fully-diluted basis.
Gerard E. Puorro, President and Chief Executive Officer, commented: “This is the third consecutive quarter of modest growth at the top line. Our expense structure is stable and we continue to look forward to enhanced factory margins. For the quarter, we were also cash positive.” Puorro continued: “Our strong distribution channels and expansive product portfolio position us well for the eventual favorable turn in the world economy. In the interim, we will continue to research and develop new products and applications that meet the needs of our customers.”